You are here: Industry Insights > Johnson & Johnson

News List

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial prnewswire
February 01, 2021
Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key ...
BioPharma Companies Announce Formation of Accumulus Synergy americanpharmaceuticalreview
January 25, 2021
Ten biopharmaceutical companies announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data ...
Johnson & Johnson’s COVID-19 vaccine safely elicits an immune response europeanpharmaceuticalreview
January 21, 2021
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
Johnson & Johnson announces initiation of rolling submission for its single-dose Janssen COVID-19 vaccine candidate with the European Medicines Agency worldpharmanews
December 07, 2020
Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention ...
Johnson & Johnson gets approval for Phase III Covid-19 vaccine trial in Spain pharmaceutical-technology
November 20, 2020
The Spanish Agency for Medicines and Health Products (AEMPS) has authorised the initiation of Phase III trials of Johnson & Johnson (J&J) unit Janssen’s Covid-19 vaccine in the country.
Janssen begins second Phase III Covid-19 vaccine trial pharmaceutical-technology
November 17, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has initiated enrolment and dosing of participants in the Phase III ENSEMBLE 2 trial of a two-dose regimen of JNJ-78436735, an investigational vaccine candidate for preventing Covid-19 ...
Aspen Pharmacare to manufacture Covid-19 vaccine candidate with J&J pharmaceutical-technology
November 05, 2020
Aspen’s South African subsidiary Aspen Pharmacare has signed a preliminary agreement with two Johnson & Johnson (J&J) subsidiaries for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate.
Brazil authorises resumption of Johnson & Johnson’s Covid-19 vaccine trial pharmaceutical-technology
November 05, 2020
The Brazilian Health Surveillance Agency Anvisa has granted approval to Johnson & Johnson (J&J) for resuming a clinical trial of its experimental Covid-19 vaccine in the country.
J&J to test COVID-19 vaccine in youths aged 12-18 expresspharma
November 02, 2020
Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, and the company’s previous experience with the same technology in a vaccine successfully used in children could give it a leg up ...
Johnson & Johnson prepares to resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 vaccine candidate in the U.S. worldpharmanews
October 28, 2020
Johnson & Johnson is preparing to resume recruitment in the pivotal Phase 3 ENSEMBLE trial of its investigational Janssen COVID-19 vaccine in the United States after a temporary pause.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page